A United States federal jury in Colorado has awarded $383.5 million to the families of three patients who claimed they suffered cardiac arrests and died after receiving dialysis treatments at clinics run by DaVita Inc.
Attorneys for the families argued DaVita was negligent and concealed facts from the patients.
“DaVita ignored many red flags that preceded the loss of life of these three patients and many others,” lead trial attorney Rob Carey said in a statement.
The United States federal jury awarded each of the three families $125 million in punitive damages, with compensatory damages ranging from $1.5 million to $5 million, according to The Denver Post.
The U.S. Food and Drug Administration recalled GranuFlo in 2012, and the wrongful deaths lawsuits were filed against DaVita in 2013 but it could be a while until the families are awarded the payout.
“We strongly disagree with this jury’s verdict and will vigorously pursue all appeal rights,” DaVita said in a press release.
The release went on to claim there was substantial evidence that the GranuFlo product is safe and effective, and no evidence that DaVita or the manufacturer of GranuFlo hid any data contradicting its safety or effectiveness.
“Our first priority is the safety of our patients. Our clinical outcomes – among the best in the industry – demonstrate our commitment to providing the highest level of care,” DaVita’s statement read.
“We will pursue any and all avenues of appeal to overcome this unjust verdict and believe the verdict is unlikely to stand.”
DaVita Inc., a Fortune 500 company and is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease.
As of March 31, 2018, DaVita Kidney Care operated or provided administrative services at 2,539 outpatient dialysis centers located in the United States serving approximately 198,000 patients.